After combing through Cat’s FidoCure DNA sequencing results (previous article), Craig and I decided to pass on the recommended treatment for CDKN2A since targeting had not been proven to be effective; no sense in subjecting her to a drug that might not work.

The other two potential therapies appeared to be more promising. After grueling research on these drugs, we preliminarily landed on addressing the remaining two mutations with the targeted therapies that the FidoCure report suggested: Rapamycin (Sirolimus) to wage war on the PIK3CA mutation and Vorinostat to take on P53.

We discussed this with our veterinarian, Dr. Miller from Partner Vet Clinic in Richmond, VA (on a Saturday, no less). She agreed with this treatment pathway — though added that Cat would be her first patient on those two targeted therapies. That marks the second time we’ve been told Cat’s cancer treatment is in uncharted territory.

Somehow, that is both daunting and hopeful.

Update: There was some confusion on how we’d go about obtaining the 2 drugs. As it turns out, your veterinarian just needs to send the prescription to FidoCure, and then FidoCure’s partner pharmacy will reach out to you directly to secure payment. They will then send the drugs to you via FedEx within a couple of days. About time for something simple!